Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared AI breast cancer detection suite by iCAD (acquired by RadNet 2025). ProFound AI reads 40M+ mammograms globally with 23% improved detection rate.
Profound AI is the medical imaging AI brand developed by iCAD, a pioneer in cancer detection technology. iCAD's ProFound AI platform applies deep learning to mammography analysis, providing radiologists with AI-powered decision support that identifies suspicious lesions, calculates cancer risk scores, and prioritizes reading worklists based on AI-assessed urgency. The system is designed to function as a second reader — augmenting rather than replacing radiologist judgment — by flagging findings that warrant closer attention and reducing the cognitive load on radiologists reviewing high volumes of routine screening mammograms.\n\nProFound AI has achieved FDA clearance as a medical device for breast cancer detection, enabling its use in clinical radiology workflows across US health systems. The platform processes mammograms in real time, integrating with existing PACS and radiology information systems so it can be deployed without disrupting established workflow. Its clinical validation studies have demonstrated a 23% improvement in cancer detection rate compared to unassisted reads, while simultaneously reducing false positives — a combination that is clinically meaningful and commercially compelling for radiology practices seeking to improve outcomes without adding radiologist time.\n\nProFound AI reads over 40 million mammograms globally, making it one of the most widely deployed FDA-cleared AI systems in radiology. iCAD was acquired by RadNet in 2025, integrating ProFound into one of the largest radiology network operators in the United States. This acquisition significantly expands ProFound's deployment footprint, as RadNet operates hundreds of imaging centers across the US and has the scale to make AI-assisted mammography a standard-of-care offering. The combination of FDA clearance, proven clinical performance, massive global deployment, and integration into a major radiology network positions ProFound AI as a market-defining product in cancer detection AI.
Oracle Corporation's cloud ERP for SMBs (40,000+ customers, 219 countries); NetSuite Next's Ask Oracle natural language AI assistant (SuiteWorld 2025), single-platform financial/CRM/inventory competing with SAP Business One.
NetSuite is a San Mateo, California and Austin, Texas-based cloud enterprise resource planning (ERP) platform and business unit of Oracle Corporation (NYSE: ORCL) — serving over 40,000 customers in 219 countries and territories with cloud-native financial management, CRM, inventory, supply chain, human capital management, and e-commerce applications designed for small-to-midsize businesses and rapidly growing enterprises that need unified business management software from a single cloud platform. NetSuite was founded in 1998 as NetLedger (one of the world's first cloud-based ERP systems) and acquired by Oracle in 2016 for $9.3 billion. Oracle's platform integration — connecting NetSuite to Oracle Cloud Infrastructure (OCI), Oracle Analytics Cloud, and Oracle's AI layer — enables NetSuite to leverage hyperscale compute, data warehousing, and generative AI capabilities that independent ERP vendors cannot build at equivalent cost. At SuiteWorld 2025, NetSuite unveiled NetSuite Next, featuring Ask Oracle — a natural language AI assistant enabling business users to search records, navigate workflows, analyze financial data, and trigger business actions across the entire NetSuite dataset through conversational queries rather than menu navigation — advancing toward autonomous AI-driven business management. The Oracle leadership transition (co-CEOs Clay Magouyrk and Mike Sicilia replacing Safra Catz) underscores Oracle's commitment to accelerating cloud product innovation across NetSuite, Oracle Cloud ERP (Fusion), and Oracle's SaaS portfolio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.